TIL Cells for the Treatment of the Advanced Solid Tumors Patients
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TILs)
therapy in patients with Advanced malignant solid tumors. TILs are expanded from tumor
resections or biopsies, and after ex vivo stimulation, activation and extensive expansion,
are reinfused to patients after non-myeloablative lymphocyte-depleting preparative regimen.